208 related articles for article (PubMed ID: 37946600)
1. Time to Benefit of Surgery vs Targeted Medical Therapy for Patients With Primary Aldosteronism: A Meta-analysis.
Samnani S; Cenzer I; Kline GA; Lee SJ; Hundemer GL; McClurg C; Pasieka JL; Boscardin WJ; Ronksley PE; Leung AA
J Clin Endocrinol Metab; 2024 Feb; 109(3):e1280-e1289. PubMed ID: 37946600
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular outcomes and all-cause mortality in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a meta-analysis.
Chen SY; Chen JY; Huang WC; Puar THK; Chin Kek P; Chueh JS; Lin YH; Wu VC; Study Group T
Eur J Endocrinol; 2022 Dec; 187(6):S47-S58. PubMed ID: 36315466
[TBL] [Abstract][Full Text] [Related]
3. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
Lancet Diabetes Endocrinol; 2018 Jan; 6(1):51-59. PubMed ID: 29129576
[TBL] [Abstract][Full Text] [Related]
4. Long-term mortality and cardiovascular events in patients with unilateral primary aldosteronism after targeted treatments.
Wu VC; Wang SM; Huang KH; Tsai YC; Chan CK; Yang SY; Lin LY; Chang CC; Lu CC; Lin YH; Chen YM; Chueh JS
Eur J Endocrinol; 2021 Dec; 186(2):195-205. PubMed ID: 34851859
[TBL] [Abstract][Full Text] [Related]
5. Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism.
Park KS; Kim JH; Yang YS; Hong AR; Lee DH; Moon MK; Choi SH; Shin CS; Kim SW; Kim SY
Endocr J; 2017 Jun; 64(6):623-632. PubMed ID: 28458337
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Outcomes with Surgical and Medical Management of Primary Aldosteronism.
Wachtel H; Fraker DL
Curr Cardiol Rep; 2021 Jun; 23(7):89. PubMed ID: 34081226
[TBL] [Abstract][Full Text] [Related]
7. Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
Hypertension; 2018 Sep; 72(3):658-666. PubMed ID: 29987110
[TBL] [Abstract][Full Text] [Related]
8. Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years.
Wu VC; Chueh SJ; Chen L; Chang CH; Hu YH; Lin YH; Wu KD; Yang WS;
J Hypertens; 2017 Aug; 35(8):1698-1708. PubMed ID: 28661412
[TBL] [Abstract][Full Text] [Related]
9. Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies.
Marzano L; Colussi G; Sechi LA; Catena C
Am J Hypertens; 2015 Mar; 28(3):312-8. PubMed ID: 25336498
[TBL] [Abstract][Full Text] [Related]
10. Composite Cardiovascular Outcomes in Patients With Primary Aldosteronism Undergoing Medical Versus Surgical Treatment: A Meta-Analysis.
Huang WC; Chen YY; Lin YH; Chueh JS
Front Endocrinol (Lausanne); 2021; 12():644260. PubMed ID: 34079522
[TBL] [Abstract][Full Text] [Related]
11. New-Onset Atrial Fibrillation in Patients With Primary Aldosteronism Receiving Different Treatment Strategies: Systematic Review and Pooled Analysis of Three Studies.
Tsai CH; Chen YL; Pan CT; Lin YT; Lee PC; Chiu YW; Liao CW; Chen ZW; Chang CC; Chang YY; Hung CS; Lin YH
Front Endocrinol (Lausanne); 2021; 12():646933. PubMed ID: 34108934
[TBL] [Abstract][Full Text] [Related]
12. Benefits of Surgical Over Medical Treatment for Unilateral Primary Aldosteronism.
Ahmed S; Hundemer GL
Front Endocrinol (Lausanne); 2022; 13():861581. PubMed ID: 35557845
[TBL] [Abstract][Full Text] [Related]
13. Outcomes in unilateral primary aldosteronism after surgical or medical therapy.
Puar TH; Loh LM; Loh WJ; Lim DST; Zhang M; Tan PT; Lee L; Swee DS; Khoo J; Tay D; Tan SY; Zhu L; Gani L; King TF; Kek PC; Foo RS
Clin Endocrinol (Oxf); 2021 Feb; 94(2):158-167. PubMed ID: 33058182
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism.
Satoh M; Maruhashi T; Yoshida Y; Shibata H
Hypertens Res; 2019 Jun; 42(6):817-824. PubMed ID: 30948836
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Najafzadeh M; Koeneman L; Farsani SF; Déruaz-Luyet A; Paik JM; Patorno E
JAMA Netw Open; 2022 Oct; 5(10):e2237606. PubMed ID: 36264574
[TBL] [Abstract][Full Text] [Related]
16. Long term outcome of Aldosteronism after target treatments.
Wu VC; Wang SM; Chang CH; Hu YH; Lin LY; Lin YH; Chueh SC; Chen L; Wu KD
Sci Rep; 2016 Sep; 6():32103. PubMed ID: 27586402
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular events and all-cause mortality in surgically or medically treated primary aldosteronism: A Meta-analysis.
Jing Y; Liao K; Li R; Yang S; Song Y; He W; Wang K; Yang J; Li Q; Hu J
J Renin Angiotensin Aldosterone Syst; 2021; 22(1):14703203211003781. PubMed ID: 33752505
[TBL] [Abstract][Full Text] [Related]
18. Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
JAMA Cardiol; 2018 Aug; 3(8):768-774. PubMed ID: 30027227
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of primary aldosteronism treatment on patients with primary aldosteronism and chronic kidney disease.
Nakano Y; Murakami M; Hara K; Fukuda T; Horino M; Takeuchi A; Niitsu Y; Shiba K; Tsujimoto K; Komiya C; Yokoyama M; Ikeda K; Yoshimoto T; Fujii Y; Yamada T
Clin Endocrinol (Oxf); 2023 Mar; 98(3):323-331. PubMed ID: 36367014
[TBL] [Abstract][Full Text] [Related]
20. Time-Dependent Risk of Atrial Fibrillation in Patients With Primary Aldosteronism After Medical or Surgical Treatment Initiation.
Kim KJ; Hong N; Yu MH; Lee H; Lee S; Lim JS; Rhee Y
Hypertension; 2021 Jun; 77(6):1964-1973. PubMed ID: 33866798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
